AXTI INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages AXT, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AXTI

NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of AXT, Inc. (NASDAQ: AXTI) between March 24, 2021 and April 3, 2024, both dates inclusive (the “Class Period”). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 5, 2024 in the securities class action first filed by the Firm.

SO WHAT: If you purchased AXT securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the AXT, Inc. class action, go to https://rosenlegal.com/submit-form/?case_id=24168 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 5, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) AXT, Inc. overstated its property holdings; (2) AXT, Inc. did not disclose that the attempted listing of an AXT, Inc. subsidiary in China had reportedly failed; (3) AXT, Inc. routinely engaged in environmental violations and unsafe business practices; (4) AXT’s production declined in 2023; and (5) as a result, defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the AXT, Inc. class action, go to https://rosenlegal.com/submit-form/?case_id=24168 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 9115830

KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value

Dr. Al Fayyadh at Harvard: We Leverage Technology to Tackle Global Health Challenges

KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value

Dr. Al Fayyadh at Harvard: We Leverage Technology to Tackle Global Health Challenges

RIYADH, Saudi Arabia, May 11, 2024 (GLOBE NEWSWIRE) — Dr. Majid Al Fayyadh, CEO of King Faisal Specialist Hospital and Research Centre (KFSH&RC) joined the Gulf Creatives Conference (GCC) at Harvard 2024. The event, GCC at Harvard, is organized by The Diwan, an organization run by graduate students at Harvard University. In his address, Dr. Al Fayyadh showcased the KFSH&RC’s journey since its inception in Riyadh almost five decades ago, highlighting how it has significantly reduced the need for patients to travel abroad for medical care. KFSH&RC has evolved into a premier provider of tertiary healthcare services and today offers cutting-edge treatments for heart diseases, tumors, organ transplantation, and genetic disorders.

Dr. Al Fayyadh discussed KFSH&RC’s transformation into an independent, non-profit foundation. This move, he indicated, aligns with the organization’s strategic vision to become a global healthcare innovation leader, emphasizing excellence, innovation, and investment in cutting-edge technology to tackle global health challenges.

KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value

Dr. Al Fayyadh at Harvard: We Leverage Technology to Tackle Global Health Challenges

“The Saudi Leadership has outlined a clear vision for KFSH&RC, mandated by a royal decree transitioning the hospital into an independent Sui Generis, non-profit foundation,” stated His Excellency, Dr. Al Fayyadh.

He further highlighted that this transformation seeks to elevate global healthcare standards through increased independence and flexibility. This shift will allow KSFH&RC to optimize existing services, pursue new opportunities, and direct resources toward initiatives that promote human health and well-being both within the Kingdom and internationally. Ultimately, this move reinforces KFSH&RC’s dedication to patient-centered excellence.

Dr. Al Fayyadh pointed out that KFSH&RC envisions itself as a leader in maximizing the value of healthcare spending, adhering to evidence-based practices to ensure optimal patient outcomes. It seeks to remain at the forefront of global healthcare innovation, with initiatives designed to increase health equity and access worldwide. To achieve this, KFSH&RC will continue to invest in cutting-edge medical facilities, advanced diagnostic equipment, and state-of-the-art treatment technologies. Building on existing progress in areas like CAR T-cell therapy, robotic surgeries, organ transplants, and personalized medicine, the institution aims to achieve global competitiveness. This will be further supported by fostering an exceptional workforce, pursuing Nobel Prize-caliber breakthroughs, and strengthening strategic international collaborations.

KFSH&RC CEO at GCC Harvard 2

Dr. Al Fayyadh joined a panel discussion focusing on the evolving landscape of the healthcare sector and the positive outcomes of KFSH&RC’s ongoing transformation in patient care. He also addressed current challenges and anticipated future developments within the healthcare sector, emphasizing the profound impact of the hospital’s innovations on global healthcare advancement. Additionally, Dr. Al Fayyadh highlighted the effective role of the hospital’s transformative initiatives in aligning with the objectives of the Health Sector Transformation Program and Saudi Vision 2030.

KFSH&RC is recognized as one of the leading global institutions that provide specialized healthcare, drive innovation, and serve as an advanced medical research and education hub. It is dedicated to developing medical technologies and elevating healthcare standards worldwide, forging partnerships with leading local, regional, and international institutions to deliver world-class services in clinical, research, and educational domains.

For the second year running, KFSH&RC has retained its status as the leading institution in the Kingdom and ranks 20th globally among the top 250 academic medical centers worldwide. It is also recognized as the most valuable healthcare brand in the Kingdom and the Middle East in 2024, according to Brand Finance, and has been ranked among the world’s top 250 hospitals by Newsweek Magazine.

KFSH&RC CEO at GCC Harvard 1

About King Faisal Specialist Hospital and Research Centre:

King Faisal Specialist Hospital & Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced medical research and education hub. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating healthcare standards worldwide.

The hospital has secured its position as the leading brand in the healthcare sector across the Kingdom and the Middle East, marking its second consecutive year as the most valuable healthcare brand. It ranks 9th within the Kingdom and 28th in the Middle East. The hospital distinguishes itself as the sole hospital globally to break into the top 10 brands in its country, as highlighted in two reports by “Brand Finance” on the 50 most valuable brands in Saudi Arabia and the 150 most valuable brands in the Middle East in 2024.

Due to the transformation programs and the Kingdom’s Vision 2030, launched by His Royal Highness the Crown Prince and Prime Minister – may God protect him – to enhance the Kingdom’s leadership in the global healthcare sector, KFSH&RC has emerged as a leading Academic Medical Centre in the Middle East and Africa. It maintained its 20th rank globally for the second consecutive year in 2024, according to “Brand Finance.” Additionally, it has been ranked among the top 250 hospitals globally in 2024 by the American magazine “Newsweek.”

For further information, please contact:

Mr. Essam AlZahrani, Acting Head of Media Affairs, 0555254429

Mr. Abdullah Alown, Media Coordination Officer, 0556294232

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d9d0ed27-fa87-49ac-b72b-ccf5b5843637
https://www.globenewswire.com/NewsRoom/AttachmentNg/682fadee-20a5-4328-bf00-e036bc3350fd

GlobeNewswire Distribution ID 9115814

KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence

KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence

RIYADH, Saudi Arabia, May 10, 2024 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSH&RC) has experienced a year of achievements across its three Centres of Excellence—Oncology, Genomics, and Transplantation.

KFSH&RC’s Oncology Centre of Excellence continues to lead the fight against the disease in the Kingdom. This year alone, the centre has treated 25% of all cancer cases in Saudi Arabia, achieving a 50% overall recovery rate and up to 90% recovery in leukemia cases. With almost five decades of service, the centre’s commitment to providing advanced cancer treatments is evident in its adoption of technologies such as CAR T-cell therapy and liquid biopsy, which provide less invasive alternatives to traditional methods, along with extensive bone marrow transplants, and revolutionary techniques like Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence

Notably, KFSH&RC has achieved a milestone by completing over 100 CAR T-cell therapy procedures, a novel treatment that genetically modifies a patient’s immune cells to fight cancer. This achievement puts it on par with renowned institutions that are also advancing CAR-T cell therapy for various blood cancers and exploring expanded applications through clinical trials and new treatment protocols. Furthermore, the centre’s focus on pediatric oncology boasts a 97% five-year survival rate for renal tumors and a 92% survival rate for acute lymphoblastic leukemia in children.

With rapid advancements in genomic medicine, KFSH&RC is adopting next-generation sequencing technologies into patient care in its Genomic Centre, revolutionizing local and regional approaches to disease management. KFSH&RC’s discovery of the bacterial strain Stenotrophomonas Riyadhensis, facilitated by whole-genome sequencing (WGS) technology, has contributed to our understanding of bacterial antibiotic resistance mechanisms. With 15,698 patient visits and over 5,658 whole genomes completed in 2023, the centre ensures that prevention, diagnosis, and treatment are precise and personalized.

KFSH&RC’s Organ Transplant Centre of Excellence (OTCoE) continues to be the primary contributor to organ transplantation activities in the Kingdom, accounting for 65% of all transplants performed nationally. In 2023, OTCoE performed 1,092 solid organ transplants, including the world’s first fully robotic liver transplant— where doctors employed robotic technology to conduct surgery on both patient and donor — an achievement that places the centre at the forefront of global transplantation practices.

As KFSH&RC continues to push the boundaries of what is possible in medical science, its efforts not only inspire but also significantly impact the global healthcare community, reaffirming its role as a leader in medical innovation and specialized healthcare.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2024, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally for the second consecutive year. Additionally, in 2024, it was recognized as one of the leading global healthcare providers by Newsweek magazine.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.

CONTACT INFORMATION

For more information, please contact:

Mr. Essam Al-Zahrani, Acting Media Affairs Head, 0555254429

Mr. Abdullah Al-Aown, Media Coordination Officer, 0556294232

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e99afd2f-d5c6-400e-9290-26b36a580bee

GlobeNewswire Distribution ID 9115490

‫ثورة في عالم التنافس والتداول: تعاون AlphaX مع رائد سباقات فورميلا تو إنزو فيتيبالدي

سيدني، أستراليا – 10 مايو 2024 – تعلن AlphaX المنصة الرائدة في تداول العملات المشفرة، والمتخصصة في صياغة مستقبل التداول بكل فخر وضع حجر الأساس لشراكتها مع سائق سباقات فورميلا تو (F2) إنزو فيتيبالدي. هذا التعاون يميز تقاربًا قائمًا بين سباقات السرعة الفائقة وتكنولوجيا التداول العصرية ويهدف إلى هدفٍ مشتركٍ وهو الجمع بين السرعة والابتكار للفوز بالمستقبل.

وقد تأسست منصة AlphaX على الشفافية والابتكار وتقدِّم مجموعة متنوعة من حلول التداول لهواة تداول العملات المشفرة. من التداول الفوري والمشتقات المتطورة. تمد AlphaX المستخدمين بأدوات متطورة حديثة للإبحار في العالم الديناميكي للأصول المشفرة. كما استحدثت AlphaX مزايا متطورة مثل تداول الإيردروب ومكافأة المتداولين على التداول، و Snipe Meme ومحفظة أدوات لسهولة شراء الأصول الموجودة في التشين. ومن خلال هذه التطورات تواصل AlphaX إعادة صياغة تجربة التداول من جديد.

إنزو فيتيبالدي النجم الصاعد في عالم سباقات فورميلا تو وسليل أسرة فيتيبالدي الشهيرة في عالم السباقات التي تجمع بين الابتكار والتميز. في الميدان المتسارع لسباق السيارات الذي يمكن أن تحدد فيه أجزاءً من الثانية الفائز من الخاسر حيث السرعة والدقة وطريقة القيادة مهمة للغاية. هناك رؤية مشتركة بين AlphaX وإنزو فيتيبالدي إلا وهي تجاوز الحواجز واحتواء التحديات لتحقيق النجاح. تهدف AlphaX من خلال هذه الشراكة إلى إشراك قاعدة جماهيرية أوسع من خلال زيادة حب سباقات السيارات على مستوى العالم ودمجها مع العالم المثير لتداول العملات المشفرة.

وقد قال المدير التنفيذي لمنصة AlphaX نحن متحمسون لبدء هذه الرحلة الشيقة مع إنزو فيتيبالدي، فهذه الشراكة تمثل دمجًا بين السرعة والابتكار والتفوق ونحن متعطشون لإحداث ثورة عند ملتقى التسابق والتداول. فمن خلالهما معًا نمضي بخطىً حثيثة متزنة نحو المستقبل محددين معاييرًا جديدة للأداء محطمين حواجز الممكن.

ومع تأهب AlphaX و فيتيبالدي يتوقع العالم تعاونًا مثيرًا للتنافس ومحفزً للتداول ليمهد الطريق نحو مستقبل حماسي.

AlphaX

AlphaX Exchange منصة رائدة في تداول العملات المشفرة متخصصة في اكتشاف العملات المشفرة التي تركز على القيمة وتعزز هذه العملات المشفرة. ونظرًا لأن لدى الشركة أساسًا راسخًا بناه خبراء المجال والتزامًا بأمن المستخدم ورضاه، لذا فإن AlphaX هي مدخلك لمستقبل الاستثمار. انضم إلينا ونحن نواصل سبر أغوار غاية سوق العملات المشفرة، أحد أصول التداول الناجحة في عصرها.

Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 12, 2024

REGULATED INFORMATION
May 10, 2024, 7:00am CET / 1:00am ET

NYXOAH SA
(Euronext Brussels: NYXH)
Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium
(hereinafter the “Company”)

Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company
to be held on June 12, 2024

The board of directors of the Company is pleased to invite its securities holders to attend the annual shareholders’ meeting of the Company, to be held on Wednesday, June 12, 2024 at 2:00 p.m. CET at the Company’s seat, or at such other place as will be indicated prior to such time. The annual shareholders’ meeting will be followed immediately by an extraordinary shareholders’ meeting.

The Company will also set up a video conference to allow holders of securities of the Company who have duly registered for the annual and the extraordinary shareholders’ meetings to follow the meetings remotely and ask questions, as the case may be in writing, during the meetings. The modalities to attend the meetings via video conference will be communicated to the relevant securities holders in due time. The videoconference will not qualify as an electronic communication tool to attend and vote at the shareholders’ meetings as referred to in Article 7:137 of the Belgian Code of Companies and Associations, but will be an extra facility for securities holders to follow the shareholders’ meetings. Holders of securities wishing to attend the meetings via video conference and also validly vote on the items on the agendas, are invited to exercise their voting rights prior to the shareholders’ meetings by following the rules set out in this convening notice, either by voting remotely by mail, or by giving a proxy to a representative of the Company.

In order to facilitate the keeping of the attendance list on the day of the annual and the extraordinary shareholders’ meetings, the holders of securities issued by the Company and their representatives are invited to register as from 1:30 p.m. CET.

AGENDA OF THE ANNUAL SHAREHOLDERS’ MEETING

  1. Acknowledgement and discussion of:
  1. the statutory annual accounts for the financial year ended on December 31, 2023;
  2. the consolidated financial statements for the financial year ended on December 31, 2023;
  3. the annual report of the board of directors on the statutory annual accounts for the financial year ended on December 31, 2023;
  4. the annual report of the board of directors on the consolidated financial statements for the financial year ended on December 31, 2023;
  5. the statutory auditor’s report on the statutory annual accounts for the financial year ended on December 31, 2023; and
  6. the statutory auditor’s report on the consolidated financial statements for the financial year ended on December 31, 2023.

1.      Approval of the statutory annual accounts for the financial year ended on December 31, 2023 and the proposed allocation of the result

Proposed decision: The shareholders’ meeting decides to approve the annual accounts for the financial year ended on December 31, 2023 and the allocation of the result as proposed by the board of directors.

2.      Discharge of directors

Proposed decision: The shareholders’ meeting decides to grant discharge to each of the directors who was in office during the financial year ended on December 31, 2023 for the performance of their mandate during that financial year.

3.      Discharge of the statutory auditor

Proposed decision: The shareholders’ meeting decides to grant discharge to the statutory auditor who was in office during the financial year ended on December 31, 2023 for the performance of his mandate during that financial year.

4.      Acknowledgement and approval of the remuneration report

Proposed decision: The shareholders’ meeting decides to approve the remuneration report.

  1. Acknowledgement and approval of the amended remuneration policy to allow for a share-based remuneration for the non-executive directors

Upon the recommendation of the remuneration committee, the board of directors proposes to amend the remuneration policy of the Company to allow for the granting of so-called “restricted share units” or “RSUs” to non-executive directors. This RSU remuneration component replaces the existing share-based remuneration in the form of a grant of warrants to non-executive directors as approved by the annual shareholders’ meeting of June 8, 2022. The proposed features of the RSUs are summarized in the proposed amended remuneration policy.

Proposed decision: The shareholders’ meeting decides to approve (a) the amended remuneration policy, (b) the granting to non-executive directors of “restricted share units” or “RSUs” as further described in the amended remuneration policy, whereby the RSUs shall be awarded for the first time as of the date of this shareholders’ meeting, and (c) the cancellation as of the date of this shareholders’ meeting of the current warrant component of the non-executive directors’ remuneration as approved by the annual shareholders’ meeting of June 8, 2022.

  1. Appointment of Robelga SRL (permanently represented by Robert Taub) as director

Proposed decision: The shareholders’ meeting decides to appoint Robelga SRL, permanently represented by Robert Taub, as director of the Company until the annual shareholders’ meeting to be held in 2025. The mandate of Robelga SRL will be remunerated as provided for the non-executive members of the board of directors in the Company’s remuneration policy as adopted by the shareholders’ meeting and, as concerns the cash remuneration, as decided by the annual shareholders’ meeting of June 8, 2022.

1.      Reappointment of Jürgen Hambrecht as independent director

Proposed decision: The shareholders’ meeting decides to reappoint Jürgen Hambrecht as an independent director of the Company within the meaning of Article 7:87 of the CCA and provision 3.5 of the 2020 Belgian Corporate Governance Code, until the annual shareholders’ meeting to be held in 2025. The mandate of Jürgen Hambrecht will be remunerated as provided for the non-executive members of the board of directors in the Company’s remuneration policy as adopted by the shareholders’ meeting and, as concerns the cash remuneration, as decided by the annual shareholders’ meeting of June 8, 2022.

2.      Reappointment of Kevin Rakin as independent director

Proposed decision: The shareholders’ meeting decides to reappoint Kevin Rakin as an independent director of the Company within the meaning of Article 7:87 of the CCA and provision 3.5 of the 2020 Belgian Corporate Governance Code, until the annual shareholders’ meeting to be held in 2025. The mandate of Kevin Rakin will be remunerated as provided for the non-executive members of the board of directors in the Company’s remuneration policy as adopted by the shareholders’ meeting and, as concerns the cash remuneration, as decided by the annual shareholders’ meeting of June 8, 2022.

3.      Reappointment of Rita Johnson-Mills as independent director

Proposed decision: The shareholders’ meeting decides to reappoint Rita Johnson-Mills as an independent director of the Company within the meaning of Article 7:87 of the CCA and provision 3.5 of the 2020 Belgian Corporate Governance Code, until the annual shareholders’ meeting to be held in 2025. The mandate of Rita Johnson-Mills will be remunerated as provided for the non-executive members of the board of directors in the Company’s remuneration policy as adopted by the shareholders’ meeting and, as concerns the cash remuneration, as decided by the annual shareholders’ meeting of June 8, 2022.

4.      Reappointment of Virginia Kirby as independent director

Proposed decision: The shareholders’ meeting decides to reappoint Virginia Kirby as an independent director of the Company within the meaning of Article 7:87 of the CCA and provision 3.5 of the 2020 Belgian Corporate Governance Code, until the annual shareholders’ meeting to be held in 2025. The mandate of Virginia Kirby will be remunerated as provided for the non-executive members of the board of directors in the Company’s remuneration policy as adopted by the shareholders’ meeting and, as concerns the cash remuneration, as decided by the annual shareholders’ meeting of June 8, 2022.

5.      Reappointment of Wildman Ventures LLC (permanently represented by Daniel Wildman) as independent director

Proposed decision: The shareholders’ meeting decides to reappoint Wildman Ventures LLC, permanently represented by Daniel Wildman, as an independent director of the Company within the meaning of Article 7:87 of the CCA and provision 3.5 of the 2020 Belgian Corporate Governance Code, until the annual shareholders’ meeting to be held in 2025. The mandate of Wildman Ventures LLC will be remunerated as provided for the non-executive members of the board of directors in the Company’s remuneration policy as adopted by the shareholders’ meeting and, as concerns the cash remuneration, as decided by the annual shareholders’ meeting of June 8, 2022.

6.      Reappointment of Pierre Gianello as director

Proposed decision: The shareholders’ meeting decides to reappoint Pierre Gianello as director of the Company until the annual shareholders’ meeting to be held in 2025. The mandate of Pierre Gianello will be remunerated as provided for the non-executive members of the board of directors in the Company’s remuneration policy as adopted by the shareholders’ meeting and, as concerns the cash remuneration, as decided by the annual shareholders’ meeting of June 8, 2022.

7.      Reappointment of Olivier Taelman as director

Proposed decision: The shareholders’ meeting decides to reappoint Olivier Taelman as director of the Company until the annual shareholders’ meeting to be held in 2025. The mandate of Olivier Taelman will not be remunerated.

AGENDA OF THE EXTRAORDINARY SHAREHOLDERS’ MEETING

  1. Acknowledgment and discussion of the special report by the board of directors drawn up in accordance with article 7:199 of the Belgian Code of Companies and Associations relating to the proposal to renew the authorized capital

8.      Renewal of the authorization to the board of directors to increase the share capital within the framework of the authorized capital

Proposed decision: The shareholders’ meeting resolves to renew the authorization to the board of directors to increase the share capital in one or several times, during a period of five (5) years as from the publication in the Annexes to the Belgian Official Gazette of this authorization, with an aggregate amount equal to EUR 3,436,000, and this in accordance with the terms and conditions set forth in the special report of the board of directors prepared in accordance with Article 7:199 of the Belgian Code of Companies and Associations, as referred to in agenda item 1 of this extraordinary shareholders’ meeting.

Consequently, the shareholders’ meeting resolves to delete the first and second paragraph of Article 7 (“Authorized capital”) of the articles of association of the Company entirely and to replace such first and second paragraph of Article 7 respectively with the following text (whereby (i) the date referred to between brackets in the second paragraph shall be the date of the shareholders’ meeting approving the renewed authorized capital, and (ii) the other provisions of Article 7 remain in place and are re-approved):

A)   text of the first paragraph: “The board of directors is authorized to increase the capital of the company on one or several occasions in accordance with the Code of Companies and Associations by a maximum aggregate amount of EUR 3,436,000.”

B)   text of the second paragraph: “This authorization is valid for a period of five years as from the date of publication in the Annexes to the Belgian State Gazette of an extract of the minutes of the extraordinary shareholders’ meeting of the company of [date of the shareholders’ meeting approving the renewed authorized capital].”

5.      Power of attorney to the notary

Proposed decision: The shareholders’ meeting decides to grant the acting notary, and any other notary of “Berquin Notarissen”, all powers to draw up and sign a restated version of the articles of association of the Company and to file them in the appropriate data base in accordance with applicable law.

ADMISSION FORMALITIES AND PARTICIPATION IN THE SHAREHOLDERS’ MEETINGS

In order to attend the shareholders’ meetings on June 12, 2024, the holders of shares and subscription rights are requested to comply with articles 26 and 27 of the Company’s articles of association and the following formalities.

If the attendance quorum required pursuant to Article 7:153 of the Belgian Code of Companies and Associations is not met at the extraordinary shareholders’ meeting of June 12, 2024, a second extraordinary shareholders’ meeting will be convened on Monday, July 1, 2024 at 2:00 p.m. CET, to deliberate and resolve on the agenda items of the extraordinary shareholders’ meeting regardless of the share capital present or represented by the shareholders.

The holders of subscription rights issued by the Company can, in accordance with Article 7:135 of the Belgian Code of Companies and Associations only attend the shareholders’ meetings with a consultative vote.

In order to be able to participate in the annual and the extraordinary shareholders’ meetings, a holder of securities issued by the Company must satisfy two conditions: (a) be registered as holder of such securities on the registration date and (b) notify the Company, as described below.

Registration date

The registration date is May 29, 2024 at midnight (Belgian time). Only persons registered as securities holders on that date and time will be entitled to attend and (if they are shareholders) vote at the meetings. The number of securities held by the securities holder on the day of the meetings will not be taken into account.

  • Holders of registered shares or subscription rights must be registered in the Company’s share register or subscription rights register, as the case may be, by midnight (Belgian time) on May 29, 2024.
  • Holders of dematerialized shares must deliver, or have delivered, to the Company, at the latest on June 6, 2024 at midnight (Belgian time), a certificate issued by the authorized account holder or by the settlement institution certifying the number of dematerialized shares registered in the name of the shareholder in its accounts on the registration date, for which the shareholder has declared his intention to participate in the meetings. This certificate must be sent to the Company by e-mail to shareholders@nyxoah.com.

Intention to participate in the meetings

The securities holders must inform the board of directors of the Company by e-mail to shareholders@nyxoah.com no later than June 6, 2024, of their intention to participate in the meetings, indicate the number of securities for which they intend to vote, and, for holders of dematerialized shares, present proof of their registration as a shareholder on the registration date.

In order to attend the meetings, securities holders and proxy holders must prove their identity and representatives of legal entities must submit documents establishing their identity and their power of representation, at the latest immediately before the start of the meetings.

Voting by proxy or by mail

Shareholders can exercise their voting rights prior to the meetings either (i) by voting by mail or (ii) by giving a proxy to a representative of the Company.

If shareholders vote by proxy, the proxy holder will be a representative of the Company. This proxy holder may only exercise the voting right in accordance with the voting instructions contained in the proxy.

The proxy voting form and the form for voting by mail approved by the Company must be used for this purpose. These forms can be downloaded from the Company’s website (https://investors.nyxoah.com/shareholder-information > Shareholders’ Meetings).

If shareholders vote by proxy or by mail, they must, in addition to the above formalities, send by e-mail to shareholders@nyxoah.com a duly completed and signed proxy voting form or form for voting by mail. These documents must reach the Company no later than June 6, 2024.

Note that the proxy voting forms and the forms for voting by mail may be signed by using an electronic signature as provided for in Article 7:143 § 2 of the Belgian Code of Companies and Associations.

Participation in the virtual shareholders’ meetings

Securities holders wishing to participate remotely, virtually and in real time, to the Company’s annual and extraordinary shareholders’ meetings are required to confirm their participation and communicate their e-mail address to the Company by June 6, 2024 at the latest by e-mail to shareholders@nyxoah.com.

A few days before the shareholders’ meetings, securities holders who have completed this formality will receive by e-mail (at the address they will have communicated to the Company) a link, and as the case may be a user name and a password, enabling them to follow and participate in the shareholders’ meetings via their computer, tablet or smartphone.

Just before the start of the shareholders’ meetings, the securities holders will have to click on the link that will have been previously communicated to them by e-mail, and as the case may be enter their user name and password, in order to join the virtual shareholders’ meetings.

Securities holders attending the virtual shareholders’ meetings will have the opportunity to view the live broadcast of the meetings in real time and to ask questions to the directors, as the case may be in writing, during the meetings regarding the items on the agenda.

New agenda items, proposed decisions and right to ask questions

Shareholders holding at least 3% of the capital who wish to request the inclusion of new items on the agenda or to submit proposals for decision must, in addition to the above formalities, establish on the date of their request proof of ownership of the required participation in the capital and send the text of the agenda items and the proposed decisions by e-mail to shareholders@nyxoah.com no later than May 21, 2024. The request must also mention the e-mail address to which the Company will send the confirmation of receipt of the request.

The case being, the revised agenda will be published no later than May 28, 2024.

Shareholders who wish to do so may send any questions they may have to the Company, relating solely to the agendas of the annual and the extraordinary shareholders’ meetings, by e-mail to shareholders@nyxoah.com, no later than June 6, 2024. The answers to these questions will be provided during the annual and the extraordinary shareholders’ meetings in accordance with applicable law.

Documentation

All documents concerning the annual and the extraordinary shareholders’ meetings that are required by law to be made available, as well as the total number of shares and voting rights outstanding, are available on the Company’s website on: https://investors.nyxoah.com/shareholder-information. The documents are also available at the seat of the Company and can only be consulted by appointment made by e-mail (shareholders@nyxoah.com). Shareholders may also obtain a hard copy of these documents free of charge by sending an e-mail to shareholders@nyxoah.com.

The aforementioned formalities, as well as the instructions on the Company’s website and on the proxy voting forms and forms for voting by mail must be strictly observed.

Various

Quorum: There is no particular quorum requirement for the deliberation and voting of the decisions proposed in the agenda of the annual shareholders’ meeting.

In accordance with Article 7:153 of the Belgian Code of Companies and Associations, at least 50% of the share capital must be present or represented for the deliberation and voting on the decisions proposed in item 2 of the agenda of the extraordinary shareholders’ meeting.

Voting: Each share entitles the holder to one vote.

Majority: In accordance with applicable law, the decisions proposed in the agenda of the annual shareholders’ meeting and the decisions proposed in the agenda of the extraordinary shareholders’ meeting, other than agenda item 2, will be adopted if they are approved by a simple majority of the votes validly cast by the shareholders present or represented at the relevant shareholders’ meeting. In accordance with Article 7:153 of the Belgian Code of Companies and Associations, the decisions proposed in item 2 of the agenda of the extraordinary shareholders’ meeting will be adopted if they are approved by 75% of the votes validly cast by the shareholders present or represented. Blank votes and abstentions are not taken into account.

Personal data: The Company is responsible for the processing of personal data that it receives or collects from holders of securities issued by the Company and agents in connection with the Company’s shareholders’ meetings.

The processing of such data will be carried out for the purpose of organizing and holding the relevant shareholders’ meeting, including convening, registration, attendance and voting, as well as maintaining lists or registers of securities holders and for purposes of analysis of the Company’s securities holders’ base.

The data includes, but is not limited to, the following: identification data, the number and nature of a holder’s securities issued by the Company, proxies and voting instructions. This information may also be transferred to third parties for the purpose of assisting or servicing the Company in connection with the foregoing.

The processing of such data will be carried out, mutatis mutandis, in accordance with the Company’s privacy notice available on the Company’s website: https://www.nyxoah.com/privacy-notice-nyxoah.

The Company draws the attention of holders of securities issued by the Company and agents to the description of the rights they may have as data subjects, such as, inter alia, the right of inspection, the right to rectify and the right to object to processing, which are set out in the section entitled “What rights can you exercise?” of the aforementioned privacy notice.

All this is without prejudice to the applicable rules on registration, use of information and participation in shareholders’ meetings in order to exercise your rights as a data subject. For any other information relating to the processing of personal data by or on behalf of the Company, the Company can be contacted by e-mail at privacy@nyxoah.com.

The board of directors

Attachment

GlobeNewswire Distribution ID 1000949955

‫الجديد الرائد إنفيكس جي تي 20 برو فلاجشيب (Infinix GT 20 Pro): الهاتف الثوري في عالم الرياضة الإلكترونية، والخطوة الأولى نحو عالم الألعاب الشامل

الرياض، المملكة العربية السعودية، 10 مايو 2024 – تعلن إنفينكس، العلامة التجارية التقنية العصرية التي تستهدف بمنتجاتها المستهلكين الشباب، عن إطلاق هاتفها المتطور المخصص للألعاب والذي يتميز بمعالج ذي شريحتين بنسخته النهائية. إنه هاتف إنفيكس جي تي 20 برو؛ الهاتف الذكي الوحيد الذي يوفر رقاقة عرض مخصصة للألعاب في نطاق سعره، ويتميز بأدائه المميز الذي يلبي مستوى الرياضة الإلكترونية؛ وبذلك فإنه ينقل تجربة الألعاب المحمولة عبر الأجهزة والبرامج إلى آفاق جديدة.

يعبّر ويكي ني، رئيس المنتجات في إنفينكس عن حماسه حول هذا الهاتف قائلاً: “عندما يلتقي الشغف مع التكنولوجيا، فإنهما يعزفان ألحان الابتكار الذي لا حدود له. إن نجاح إنفيكس جي تي 20 برو لم يكن سوى البداية، واللحنَ الأول في سيمفونية عريقة من الأجهزة، والبرامج، وأنظمة التبريد، وتصميم السايبر-ميكا الأمني، التي تنقل عالم الهواتف إلى آفاق جديدة. إنه ليست مجرد هاتف؛ إنه نقطة تحول في عالم البطولات في الرياضة الإلكترونية المحترفة”.

كما أن إطلاق إنفينكس جي تي فيرس (Infinix GT VERSE) يرفع مستوى الألعاب، من خلال إصدار مجموعة من المنتجات تلبي متطلبات اللعب بما في ذلك كمبيوتر محمول، وسماعات أذن، وساعة ذكية، ومروحة تبريد.

تفوّق على الهواتف الأخرى

يضم الهاتف معالج Dimensity 8200 Ultimate  بتقنية 5G وتصنيع 4 نانومتر، ورقاقة عرض الألعاب المخصصة Pixelworks X5 Turbo؛ مما يجعله هاتفًا ثوريًا يوفر أداءً يلبي مستوى الرياضة الإلكترونية. كما أن زيادة معدلات الإطار من 60 إطارًا في الثانية إلى 120 إطارًا في الثانية، توفر تجارب بصرية مذهلة. سيخوض اللاعبون تجربة ألعاب آسرةً ويستمتعون بتفاعل مميز من خلال هذا الهاتف؛ فهو أول هاتف ذكي معتمد بواسطة برنامج الشهادة المعتمدة IRX تطلقه شركة إنفينكس.

أداء خارق يجعله وحش الألعاب بلا منازع

كما أنه مزوّد بميزة إكس بوست (Xboost) لإدارة الأداء المستدام، ويستخدم المزامنة العمودية لمنع تمزق الشاشة. أما عند الحديث عن المحرك، فيتميز بأنه يعطي أولويةً لموارد الألعاب، مما يضمن تجربة ألعاب سلسة وذات أداء مميز.

يتميز نظام التبريد في الهاتف بأنه نظام مصمم بعناية يستخدم ورقة الجرافيت لمادة متغيرة الطور (PCM) بحجم 68% أكبر، ونظام تبريد سائل VC بحجم 73% أكبر لتحسين كفاءة التبريد وتبديد الحرارة، كما يتم تطبيق أكثر من 66% من معجون الحرارة على المنطقة التي تشكل مصدر الحرارة الأساسية للتبريد المستهدف.

على الرغم من أن سلسلة هواتف إنفينكس جي تي (Infinix GT) دخلت حديثًا إلى ساحة الهواتف الرائدة في عالم الألعاب، إلا أنها تمكنت في غضون عام واحد فقط من أن تتألق وتصبح علامة فارقة في مجال

تسعى شركة إنفينكس إلى توفير تجربة ألعاب مميزة للمستخدمين؛ تجربةً تليق بمستوى الرياضات الإلكترونية. وأخيرًا وبعد أن أخضعت الشركةُ هاتف إنفيكس جي تي 20 برو إلى ثلاث جولات من الاختبارات الاحترافية الصارمة، أثبت جدارته واستوفى المعايير المطلوبة لاستخدامه على مستوى البطولات وأصبح الهاتف الرسمي لبطولة ببجي موبايل سوبر ليج (PMSL).

يقدم هاتف إنفيكس جي تي 20 برو أداءً استثنائيًا ويُظهر كفاءة في التعامل مع الألعاب الشهيرة كلعبة موبايل ليجيندز (MLBB)، وببجي (PUBG)، وكول أوف ديوتي (COD)، وجينشين إمباكت (Genshin Impact) وهونكاي: ستار رايل (Honkai: Star Rail). كما يمكنه رفع معدلات تحديث لعبة جينشين إمباكت إلى 120 هرتز من خلال التداخل ليوفر تجربة لعب سلسة ولا مثيل لها.

هاتف مصمم ليتفوق في عالم الألعاب

يتيمز هاتف إنفيكس جي تي 20 برو بتصميم السايبر-ميكا الذي يتماشى مع تصور إنفينكس جي تي للمعدن، والقوة، والسرعة. كما يتمتع بنمط شفرة التوربين الفريد مما يمنحه جمالًا ديناميكيًا وأداءً مميزًا. توفر واجهته ميكا لووب ليد (Mecha Loop LED) تخصيصًا واسعًا، مع ثمانية تركيبات للألوان وأربعة تأثيرات إضاءة؛ مما يتيح للاعبين تخصيصًا شاملًا لأجهزتهم. إن تصميمه الخارجي مستوحىً من البنية المعقدة لخلايا النحل، ويتماشى مع التصميمات الجميلة والنابضة بالحياة للألعاب الحديثة؛ مما يجعله الخيار الأمثل للاعبين الباحثين عن الأداء والأناقة معًا.

المزايا الرئيسية

  • شاشة المصفوفة العضوية النشطة ذات الصمام الثنائي الباعث للضوء (AMOLED) مقاس 6.78 بوصة بدقة عرض كاملة محسّنة (FHD+) ومعدل تحديث 144 هرتز بحواف رفيعة.
  • نظام التشغيل النقي والنظيف Clean & Pure OS 2.0 مع تحديثين رئيسيين لنظام أندرويد وتحديثات أمان لمدة 3 سنوات.
  • سماعات مزدوجة بتقنية صوت ماركة JBL.
  • وضع الشحن السريع – بطارية بسعة 5000 مللي أمبير وشحن سريع بقوة 45 واط.
  • تصميم سايبر-ميكا بوجود إضاءة ميكا لووب ميني ليد (Mecha Loop Mini LED) قابلة للتخصيص والتفاعل.
  • تأثيرات إضاءة الألعاب ميكا لووب.

كاميرا خلفية ثلاثية بدقة 108 ميجابكسل مزودة بتقنية تثبيت الصور الضوئي (OIS).

كما يسر شركة إنفينكس أن تعلن أيضًا عن كومبيوترها المحمول الجديد إنفينكس جي تي بي بوك (Infinix GTBOOK) الذي تم إنشاؤه بالتعاون مع شركة إنفيديا (Nvdia). يتميز هذا الكومبيوتر بتقنية وحدة المعالجة المركزية، ووحدة معالجة الرسومات المتطورة، وحلول تبريد متقدمة، وشاشة عالية معدل التحديث. تتزين هذه الميزات بتصميم أنيق يعكس التزام منتجات سلسلة إنفينكس جي تي بتصميمات تحاكي جماليات الألعاب الحديثة والتي يكون اللاعب حجر الأساس فيها.

هاتف الألعاب الرسمي لبطولة ببجي موبايل سوبر ليج

(PMSL)أصبح هاتف إنفيكس جي تي 20 برو هاتف الألعاب الرسمي لبطولة ببجي موبايل سوبر ليج

السعر والتوفر:

سيتوفر هاتف إنفيكس جي تي 20 برو باللون الأزرق الميكا، والبرتقالي الميكا، والفضي الميكا، بإعدادات ذاكرة 12+256 جيجابايت و8+256 جيجابايت. أما الأسعار فستختلف حسب المنطقة، وسيتم الإعلان عن التفاصيل عند إطلاق الهاتف

نبذة عن إنفينكس:

إنفينكس موبايليتي هي علامة تجارية تكنولوجية ناشئة تختص بتصميم وتصنيع وتسويق مجموعة متنامية من الأجهزة حول العالم التي تحمل علامة إنفينكس التي تأسست في عام 2013. تستهدف إنفينكس المستهلكين من فئة الشباب، وتصبّ اهتمامها على تطوير تكنولوجيا حديثة متقدمة تتمثل في أجهزة الهواتف المحمولة المصممة بعناية التي تتميز بطرازها الراقي، وكفاءتها العالية، وأدائها المميز. وقد اتصفت أجهزة إنفينكس بكونها عصرية ومتاحة للجميع، وتلبي احتياجات المستخدم النهائي؛ فهو جوهر كل خطوة من خطوات التطوير.

لمزيد من المعلومات، يرجى زيارة: http://www.infinixmobility.com

Infinix GT 20 Pro Flagship Launch: Esports-Level Gaming Phone Revolution and the Dawn of a Holistic Gaming Universe

RIYADH, SAUDI ARABIA – Media OutReach Newswire – 9 May 2024 – Infinix, a trendy tech brand crafted for young consumers, announces its ultimate dual-chip gaming phone, the Infinix GT 20 Pro. Being the only smartphone to offer a dedicated gaming display chip at its price point, it delivers esports-level performance, redefining the mobile gaming experience across hardware and software.
Infinix GT 20 Pro Flagship Launch

Weiqi Nie, Head of Product at Infinix excitedly shares, “Innovation knows no bounds when passion meets technology. The success of the Infinix GT 10 Pro was just the beginning. With the Infinix GT 20 Pro, we have raised the bar higher, introducing a symphony of hardware, software, cooling systems, and cyber-mecha design. It’s not just a phone; it’s a game-changer for professional esports tournaments.”

Furthermore, the introduction of the Infinix GT VERSE elevates gaming, creating a range of products including a laptop, earphones, a smartwatch, and a cooling fan.

Outplay The Rest
The Infinix GT 20 Pro sets itself apart in its price segment with dual chips that bring its performance on par with competitive flagship processors, delivering an unmatched high-performance gaming experience. Featuring the Dimensity 8200 Ultimate 4nm 5G Processor and Pixelworks X5 Turbo Dedicated Gaming Display Chip, it offers esports-level performance and visually stunning experiences, pushing frame rates from 60 FPS to 120 FPS. As the first IRX-certified smartphone launched by Infinix, players can expect a distinctively more immersive gaming experience.

Perform Like A Gaming Beast
The gaming performance of the Infinix GT 20 Pro is underpinned by a Stable Frame-rate Engine that optimizes gameplay by balancing temperature and power consumption, ensuring smooth performance with minimal power usage. It includes Xboost for sustained performance management and employs vertical synchronization to prevent screen tearing. The engine prioritizes gaming resources, guaranteeing a seamless and efficient gaming experience.

A meticulously engineered cooling system employs a 68% larger Phase Change Material (PCM) graphite sheet and a 73% larger VC Liquid Cooling system to improve cooling and heat dissipation efficiency. Additionally, more than 66% of the thermal paste is applied to the primary heat source area for targeted cooling.

The Infinix GT Series is a newcomer in the gaming flagship arena but has quickly become a shining star in the esports field within just one year. Infinix aims to provide users with an esports-level gaming experience, so after three rounds of rigorous professional testing, the Infinix GT 20 Pro has met the standards for tournament-level use and has become the Official Gaming Phone of the PUBG Mobile Super League (PMSL).

The Infinix GT 20 Pro demonstrates exceptional performance and efficiency when handling popular games including MLBB, PUBG, COD, Genshin Impact, and Honkai: Star Rail. Notably, it can upscale Genshin Impact refresh rates to 120Hz through interpolation for super-smooth gameplay.

Designed For Gaming Master
The Infinix GT 20 Pro showcases the Cyber Mecha Design, capturing the Infinix GT spirit of Metal, Power, and Speed with a unique Turbine Blade Pattern for dynamic, high-performance aesthetics. Its Mecha Loop LED Interface offers extensive customization, with eight color combinations and four lighting effects, allowing gamers to personalize their device extensively. Inspired by the intricate structure of beehives, the exterior design aligns with modern gaming’s vibrant aesthetics, making it a standout choice for gamers seeking performance and style.

Key Features
• Bezel-Less 6.78-inch 144Hz FHD+ AMOLED Display
• Clean & Pure OS 2.0 with 2 Major Android Upgrades and 3-year Security Patch Updates
• Dual Speakers with Sound by JBL
• Hyper Charge Mode – 5000mAh Battery & 45W Fast Charge
• Cyber Mecha Design with Customizable & Interactive Mecha Loop Mini LED
• Mecha Loop Game Lighting Effects
• 108MP OIS Triple Rear Camera

Vision Toward A Holistic Gaming Universe
The Infinix GT series was created to satisfy the multifaceted desires of gamers, from gameplay to enabling self-expression and beyond. The Infinix GT 20 Pro builds upon this rich heritage as part of a wider portfolio, introducing the Infinix GT VERSE, Infinix’s gaming ecosystem for all gaming enthusiasts. It features a laptop, earphones, a smartwatch, and a cooling fan, providing a full suite of tools to level up gaming.

Infinix also announces the Infinix GTBOOK, created in in collaboration with Nvdia. It boasts top-tier CPU and GPU technology, advanced cooling solutions, and a high refresh rate display. These features are encompassed within a sleek design that reflects the Infinix GT series’ commitment to cutting-edge, gamer-centric aesthetics.

Official Gaming Phone for PUBG Mobile Super League
The Infinix GT 20 Pro is the Official Gaming Phone for the PUBG Mobile Super League (PMSL). The tournament is set to take place from May 15 to June 9 in Europe, the Middle East, and Africa (EMEA), and from May 22 to June 16 in Central and South Asia (CSA). Infinix is committed to empowering all gamers with essential tools for the ultimate gaming experience.

Pricing & Availability:
The Infinix GT 20 Pro will be available in Mecha Blue, Mecha Orange, and Mecha Silver, with 12+256GB and 8+256GB memory configurations. Pricing will vary by region, with details to be announced at launch.

About Infinix:

Infinix Mobility is an emerging technology brand that designs, manufactures and markets an expanding portfolio of devices worldwide under the Infinix brand which was founded in 2013. Targeting young consumers, Infinix focuses on developing cutting-edge technology embodied in meticulously designed mobile devices that offer refined style, power and performance. Infinix devices are trendy & attainable with the end-user at the forefront of every step forward.

For more information, please visit: http://www.infinixmobility.com/

King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia

King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia

RIYADH, Saudi Arabia, May 09, 2024 (GLOBE NEWSWIRE) — Harvard University — Eight years into Vision 2030, Saudi Arabia has made significant strides with digital innovations and enhanced access to quality care. Strategic investments in infrastructure, technology, and talent, have led to advancements revolutionizing patient care delivery and elevating the standards of healthcare locally. These efforts have notably raised the average life expectancy, reduced mortality rates, and enhanced overall well-being across the Kingdom.

Central to these achievements, King Faisal Specialist Hospital & Research Centre (KFSH&RC), renowned for its specialized care and treatments across critical fields such as oncology, cardiology, organ transplantation, and genetics has positioned itself as a leader in specialized patient care, taking the charge towards a brighter, healthier future for the Kingdom. Through its commitment to pioneering digital health initiatives, comprehensive educational programs, and novel research endeavors, it is reshaping the local landscape, and setting new standards of efficiency and accessibility.

In an era defined by technological advancements, and with the Kingdom’s push towards digitalization, KFSH&RC stands at the forefront of digital health integration among its local peers, leveraging cutting-edge telemedicine services, virtual consultations, and AI-driven tools such as the ANFAL AI System that transforms patient outcomes through predictive insights and personalized care, ensuring the best outcomes for patient satisfaction.

KFSH&RC’s digital health initiatives extend to addressing broader health threats through technologies such as Whole Genomic Sequencing (WGS) and Advanced Radiation Therapy. The hospital has also pioneered organ transplantation by performing the world’s first fully robotic liver transplant and introduced to the region innovations like the Harmony Transcatheter Pulmonary Valve (TPV), enhancing patient recovery and experience. These technologies facilitate personalized treatment plans and improve the accuracy and speed of medical diagnostics, contributing significantly to the elevation of patient care standards and a sustainable, resilient healthcare infrastructure in line with the objectives of the Health Sector Transformation Program.

KFSH&RC continues to push the boundaries of medical research addressing pressing health challenges and contributing to Saudi Arabia’s public health landscape, with discoveries like the PfAP2-MRP gene crucial for malaria treatment and the identification of the new Riyadhensis bacteria strain. These discoveries have not only improved diagnostic accuracy but also facilitated early interventions, ensuring timely and effective patient support, in line with the national objectives to reduce chronic disease prevalence.

These comprehensive efforts are supported by KFSH&RC’s robust educational initiatives, which prepare the next generation of medical professionals through training programs and international collaborations.

Recognized by ‘Brand Finance’ in 2024 as the most valuable healthcare brand in Saudi Arabia and the Middle East for the second consecutive year, placing 9th in Saudi Arabia and 28th in the Middle East. Additionally, KFSH&RC stands out as the only hospital worldwide to be ranked among its country’s top ten most valuable brands.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2024, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally for the second consecutive year. Additionally, in 2024, it was recognized as one of the leading global healthcare providers by Newsweek magazine.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.

CONTACT INFORMATION

For more information, please contact:

Mr. Essam Al-Zahrani, Media Affairs Head, 0555254429

Mr. Abdullah Al-Aown, Media Coordination Officer, 0556294232

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/003e76ab-3d93-42d4-9edf-5e652a14c559

Copyright © 2024 GlobeNewswire, Inc.

GlobeNewswire Distribution ID 9114722

Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest

Curia & Carterra Biologics Symposium

Biologics symposium slated for May 31 in Seattle, WA

ALBANY, N.Y. and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization and Carterra Inc., the world leader in label-free high throughput antibody and small molecule drug discovery, today announced their partnership in hosting a high-throughput biologics symposium slated for May 31 at the Residence Inn at Marriott in Seattle, Washington.

The purpose of the collaboration is to promote the rising biotech focus within the Pacific Northwest region of the U.S and Canada. The symposium will bring together all levels of scientific leadership from the biotech and pharma communities.

“We are thrilled to be partnering with Carterra to organize this antibody discovery symposium, bringing the Pacific Northwest biotech community together and sharing the latest advances in antibody discovery,” said Steve Lavezoli, Vice President of Biologics at Curia. “We are also looking forward to sharing our optimal, high-quality and accelerated antibody discovery workflows to first-to-human antibody discovery, development and clinical manufacturing. Antibodies discovered and/or engineered with Curia’s platform technology are in the clinic and we have over 230 successful antibody discovery campaigns performed for the biotech community.”

Speed, scientific expertise and efficiency can surmount the high attrition rates of early antibody discovery and achieve first-to-market delivery of new therapeutics. The symposium will highlight Curia’s technology platform and integrated services with a focus on the development of enhanced mouse systems for antibody generation and high-throughput single B cell screening. The combination of next generation sequencing (NGS) and rapid recombinant production of milligram to gram quantities of purified monoclonal antibody (mAb) significantly accelerates identification of development candidate leads.

Since 2017, Carterra has been selling its powerful LSA® high-throughput biosensor to analyze and characterize antibodies using Surface Plasmon Resonance (SPR). With the launch of its LSAXT platform last year, Carterra now offers products that can perform small molecule analysis as well as antibody discovery. The LSA platform has been profiled in several peer-reviewed papers in Science, Nature and Cell, detailing the path of multiple therapeutics entering clinical trials. At the symposium, several leading scientists in biopharma will be sharing their insights into their specific areas of drug discovery and will highlight the transformative impact of integrating HT-SPR technology, AI/ML and other new technologies.

“We are excited to be partnering with Curia on our symposium. Carterra symposia are scientific events that we host each year throughout the U.S. and Europe,” stated Chris M. Silva, Vice President of Marketing and Product at Carterra. “These symposia help us to share the latest technology advancements and important data generated from the workflows of scientists using Carterra’s label-free platforms. Coming to the Pacific Northwest is an opportunity to create a deeper understanding of the technology in pharma and biotechs in this region.”

Click here to RSVP for the event. Registration is required as seating is limited.

About Curia:
Curia is a Contract Development and Manufacturing Organization (CDMO) with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with Biopharmaceutical customers to bring life-changing therapies to market. Our biologics and small molecules offerings span discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to improve patients’ lives. Visit us at curiaglobal.com.

About Carterra, Inc.:
Carterra, Inc. is a privately held company. Its HT-SPR technology provides large-molecule and small-molecule drug discovery customers with screening and characterization throughput and functionality that scales with omics-level applications, condensing months of work down to days. Our solutions have enabled multiple therapeutics and breakthrough research and helped academic and translational researchers and biopharmaceutical companies in oncology, immunology, neuroscience, and more.  Carterra is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity. To learn more, visit www.carterra-bio.com or connect with us on LinkedIn or X (Twitter).

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Carterra Media Contact:
Cheri Salazar
(408) 594-9400
csalazar@carterra-bio.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/020a0a28-86f0-4f6c-96f2-0eaa01c82784

GlobeNewswire Distribution ID 9114095

Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest

Curia & Carterra Biologics Symposium

Biologics symposium slated for May 31 in Seattle, WA

ALBANY, N.Y. and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization and Carterra Inc., the world leader in label-free high throughput antibody and small molecule drug discovery, today announced their partnership in hosting a high-throughput biologics symposium slated for May 31 at the Residence Inn at Marriott in Seattle, Washington.

The purpose of the collaboration is to promote the rising biotech focus within the Pacific Northwest region of the U.S and Canada. The symposium will bring together all levels of scientific leadership from the biotech and pharma communities.

“We are thrilled to be partnering with Carterra to organize this antibody discovery symposium, bringing the Pacific Northwest biotech community together and sharing the latest advances in antibody discovery,” said Steve Lavezoli, Vice President of Biologics at Curia. “We are also looking forward to sharing our optimal, high-quality and accelerated antibody discovery workflows to first-to-human antibody discovery, development and clinical manufacturing. Antibodies discovered and/or engineered with Curia’s platform technology are in the clinic and we have over 230 successful antibody discovery campaigns performed for the biotech community.”

Speed, scientific expertise and efficiency can surmount the high attrition rates of early antibody discovery and achieve first-to-market delivery of new therapeutics. The symposium will highlight Curia’s technology platform and integrated services with a focus on the development of enhanced mouse systems for antibody generation and high-throughput single B cell screening. The combination of next generation sequencing (NGS) and rapid recombinant production of milligram to gram quantities of purified monoclonal antibody (mAb) significantly accelerates identification of development candidate leads.

Since 2017, Carterra has been selling its powerful LSA® high-throughput biosensor to analyze and characterize antibodies using Surface Plasmon Resonance (SPR). With the launch of its LSAXT platform last year, Carterra now offers products that can perform small molecule analysis as well as antibody discovery. The LSA platform has been profiled in several peer-reviewed papers in Science, Nature and Cell, detailing the path of multiple therapeutics entering clinical trials. At the symposium, several leading scientists in biopharma will be sharing their insights into their specific areas of drug discovery and will highlight the transformative impact of integrating HT-SPR technology, AI/ML and other new technologies.

“We are excited to be partnering with Curia on our symposium. Carterra symposia are scientific events that we host each year throughout the U.S. and Europe,” stated Chris M. Silva, Vice President of Marketing and Product at Carterra. “These symposia help us to share the latest technology advancements and important data generated from the workflows of scientists using Carterra’s label-free platforms. Coming to the Pacific Northwest is an opportunity to create a deeper understanding of the technology in pharma and biotechs in this region.”

Click here to RSVP for the event. Registration is required as seating is limited.

About Curia:
Curia is a Contract Development and Manufacturing Organization (CDMO) with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with Biopharmaceutical customers to bring life-changing therapies to market. Our biologics and small molecules offerings span discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to improve patients’ lives. Visit us at curiaglobal.com.

About Carterra, Inc.:
Carterra, Inc. is a privately held company. Its HT-SPR technology provides large-molecule and small-molecule drug discovery customers with screening and characterization throughput and functionality that scales with omics-level applications, condensing months of work down to days. Our solutions have enabled multiple therapeutics and breakthrough research and helped academic and translational researchers and biopharmaceutical companies in oncology, immunology, neuroscience, and more.  Carterra is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity. To learn more, visit www.carterra-bio.com or connect with us on LinkedIn or X (Twitter).

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Carterra Media Contact:
Cheri Salazar
(408) 594-9400
csalazar@carterra-bio.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/020a0a28-86f0-4f6c-96f2-0eaa01c82784

GlobeNewswire Distribution ID 9114095

Arqit warns CISOs why they must act now to secure their data ready for the post-quantum world

LONDON, May 09, 2024 (GLOBE NEWSWIRE) — Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit), a leader in quantum-safe encryption, today urges CISOs and security teams to urgently address their post-quantum technology strategies, as quantum computing advances rapidly. The risk of Store Now, Decrypt Later (SNDL) attacks underscores that the quantum threat is not a distant concern but an immediate security challenge demanding attention today.

Arqit’s distinctive approach addresses the cost and complexity associated with quantum-safe migration strategies through its ground breaking Symmetric Key Agreement Platform (SKA Platform™). Mitigating the risks posed by SNDL attacks is paramount to safeguarding valuable long-term data. Failure to do so could result in a catastrophic breach of data privacy, threatening the secrecy of sensitive and classified information.

Further details may be found in the IDC Analysts Brief: “Securing Valuable and Durable Data in a Post-Quantum World”, sponsored by Arqit

Securing Valuable and Durable Data in a Post-Quantum World (arqit.uk)

David Williams, Chairman and CEO of Arqit Limited said:

“Our cloud-based solution is designed for today’s modern and evolving network environments. Protecting data transmission across diverse communication links and device types necessitates security that is easily deployable, scalable and integrates seamlessly into existing infrastructures without the need for additional hardware. By using well established cryptographic techniques grounded in quantum-resistant symmetric encryption methods, Arqit offers organisations a distinct pathway to transition seamlessly into the post-quantum era.”

Notes to Editors

Arqit representatives will be attending RSA (6-9 May 2024) and will be available for interview. www.rsaconference.com/usa.

For more information about Arqit visit Arqit’s website

IDC Analysts Brief: “Securing Valuable and Durable Data in a Post-Quantum World”, published May 2024, document number IDC #EUR252099724

International Data Corporation (IDC) is the premier global provider of market intelligence, advisory services, and events for the information technology, telecommunications and consumer technology markets. IDC helps IT professionals, business executives, and the investment community to make fact-based decisions on technology purchases and business strategy. For additional information on IDC, please visit https://www.idc.com.

About Arqit

Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit) supplies a unique encryption software service which makes the communications links of any networked device, cloud machine or data at rest secure against both current and future forms of attack on encryption – even from a quantum computer. Compatible with NSA CSfC Components and meeting the demands of NSA CSfC Symmetric Key Management Requirements Annexe 1.2. and RFC 8784, Arqit’s Symmetric Key Agreement Platform uses a lightweight software agent that allows end point devices to create encryption keys locally in partnership with any number of other devices. The keys are computationally secure and facilitate Zero Trust Network Access. It can create limitless volumes of keys with any group size and refresh rate and can regulate the secure entrance and exit of a device in a group. The agent is lightweight and will thus run on the smallest of end point devices. The product sits within a growing portfolio of granted patents. It also works in a standards compliant manner which does not oblige customers to make a disruptive rip and replace of their technology. Arqit is winner of two GSMA Global Mobile Awards, The Best Mobile Security Solution and The CTO Choice Award for Outstanding Mobile Technology, at Mobile World Congress 2024, recognised for groundbreaking innovation at the 2023 Institution of Engineering and Technology Awards and winner of the National Cyber Awards’ Innovation in Cyber Award and the Cyber Security Awards’ Cyber Security Software Company of the Year Award. Arqit is ISO 27001 Standard certified. www.arqit.uk

Media relations enquiries:
Arqit: pr@arqit.uk

Investor relations enquiries:
Arqit: investorrelations@arqit.uk
Gateway: arqit@gateway-grp.com

Caution About Forward-Looking Statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, may be forward-looking statements. These forward-looking statements are based on Arqit’s expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. These factors are difficult to predict accurately and may be beyond Arqit’s control. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for Arqit to predict these events or how they may affect it. Except as required by law, Arqit does not have any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date this communication is issued. In light of these risks and uncertainties, investors should keep in mind that results, events or developments discussed in any forward-looking statement made in this communication may not occur. Uncertainties and risk factors that could affect Arqit’s future performance and cause results to differ from the forward-looking statements in this release include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against the Arqit, (ii) the ability to maintain the listing of Arqit’s securities on a national securities exchange, (iii) changes in the competitive and regulated industries in which Arqit operates, variations in operating performance across competitors and changes in laws and regulations affecting Arqit’s business, (iv) the ability to implement business plans, forecasts, and other expectations, and identify and realise additional opportunities, (v) the potential inability of Arqit to successfully deliver its operational technology, (vi) the risk of interruption or failure of Arqit’s information technology and communications system, (vii) the enforceability of Arqit’s intellectual property, and (viii) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Arqit’s annual report on Form 20-F (the “Form 20-F”), filed with the U.S. Securities and Exchange Commission (the “SEC”) on 21 November 2023 and in subsequent filings with the SEC. While the list of factors discussed above and in the Form 20-F and other SEC filings are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realisation of forward-looking statements.

GlobeNewswire Distribution ID 9113888

‫شراكة تجمع مجموعة أباريل و ” Sandbox VRساندبوكس في آر” لجلب ابتكارات الواقع الافتراضي إلى الشرق الأوسط

ستثمر هذه الشراكة عن 25 موقعاً في الشرق الأوسط بحلول عام 2028

شراكة تجمع مجموعة أباريل و ” Sandbox VRساندبوكس في آر” لجلب ابتكارات الواقع الافتراضي إلى الشرق الأوسط
· ستثمر هذه الشراكة عن 25 موقعاً في الشرق الأوسط بحلول عام 2028

دبي، الإمارات العربية, May 09, 2024 (GLOBE NEWSWIRE) —  – ضمن مساعيها السبّاقة، تتعاقد مجموعة أباريل ذات المكانة الريادية العالمية في مجالات التجزئة وأسلوب الحياة، مع Sandbox VR ” ساندبوكس في آر” وهي الوجهة الأولى في العالم لتجربة متميزة في عالم الواقع الافتراضي المقدمة في الموقع، في سبيل تنسيق الجهود ضمن شراكة امتياز هامة. ويعوّل في هذا التعاون على سيادة مجموعة أباريل في المنطقة من خلال أكثر من 2200 متجراً لما يزيد عن 85 علامة تجارية تابعة لها في 14 دولة، ويبتدئ التعاون بـ 25 موقعاً في الشرق الأوسط. جاءت هذه الشراكة على أعقاب حيازة ” ساندبوكس في آر” على المركز الثاني عن فئة الواقع الافتراضي والواقع المعزز في القائمة المرموقة للشركات العالمية الرائدة في الابتكار لعام 2024 بحسب تصنيفات“Fast Company” ، نظراً لشهرتها الواسعة في تكوين تجربة واقع افتراضي آسر لجميع المستخدمين من شتى أنحاء العالم.

وقد علق نيراج تيكشينداني، الرئيس التنفيذي لمجموعة أباريل على هذه الشراكة بقوله: ” نحن متحمسون للشروع بهذه الشراكة مع ” ساندبوكس في آر “، كونها في طليعة الابتكارات في الواقع الافتراضي”، وأضاف ” لا يقتصر هذا التعاون على توسيع ملف أعمالنا فحسب، بل يعد بإنشاء تجارب خلّاقة تدمج بين التكنولوجيا والترفيه، وهذه هي التجربة الفريدة التي نتطلع لنوفرها لعملائنا في الشرق الأوسط وفي سائر المناطق، لنضع من خلالها معايير جديدة في قطاعي الترفيه والبيع بالتجزئة”.

وقال ستيف زاو، المؤسس والرئيس التنفيذي لشركة ساندبوكس في آر: ” لقد سررننا بردود الأفعال الإيجابية في مواقعنا في الولايات المتحدة الأمريكية وأوروبا وآسيا” وتابع بقوله ” تحظى التجارب التي نبتكرها على إقبال عالمي لا مثيل له. ونحن متحمسون للتعاون مع مجموعة أباريل لتوسيع بصمتنا العالمية، ولنقدم تجربة غامرة في عالم الواقع الافتراضي تسر المستخدمين في جميع أنحاء العالم”.

تنشط ” ساندبوكس في آر ” عبر أكثر من 46 موقعاً عالمياً وتتوسع بشكل ملحوظ وهائل. ومع إطلاق 18 موقعاً خلال الأشهر الـ 19 الأخيرة، بمساحات تزيد عن 4000 قدم مربع لكل منها مع نظم “هولوديك” المتعددة والتي تقدم الواقع الافتراضي للمستخدمين، تعد شركة ” ساندبوكس في آر” من الشركات الناشئة الواعدة في مجال الواقع الافتراضي المقدم في الموقع، والأسرع نمواً في العالم. ولتعزيز توسعها أعلنت الشركة مؤخراً عن افتتاحها برنامج حقوق الامتياز لوضع بصمتها في الولايات المتحدة الأمريكية بالإضافة إلى مواقعها حول العالم. وفي إطار التزامها المستمر في الشمولية، تعمل ” ساندبوكس في آر ” على توفير تجربة للمستخدمين متعددة اللغات وحالياً تتوفر بإجمالي سبع لغات وهي في ازدياد مستمر، وهذا ما يمكّنها من إيصال التجربة الغامرة إلى جمهور أكبر.

وقال لي هيبديتش، مدير شؤون حقوق الامتياز العالمية لدى ساندبوكس في آر: ” يعد توسعنا في الشرق الأوسط خطوة استراتيجية نحو التزامنا العالمي في تقريب الناس بعضهم من بعض، عبر تجارب آسرة رفيعة المستوى”، ثم أضاف “وإن السيادة الإقليمية التي تتمتع بها مجموعة أباريل والإنجازات الاستثنائية التي حققتها يجعلها الحليف العالمي الأمثل لشركتنا، ونحن مستمرون في مهمتنا لجعل التسلية في المواقع متاحة بشكل أكبر”.

ويُذكر في سبتمبر 2023، تعاون شركة ” ساندبوكس في آر” مع ” نتفليكس ” التي تم من خلالها إطلاق لعبة ” Squid Game ” الافتراضية الحصرية، والمستوحاة من المسلسل الحائز على مرتبة الصدارة في المشاهدات. وحققت اللعبة الافتراضية نجاحاً باهراً حطمت من خلاله أرقاماً قياسية كونها أسرع تجربة افتراضية تصل مبيعاتها إلى مليون دولار أمريكي. وفي أول شهرين لهذه اللعبة، حققت 4.56 مليون دولار أمريكي من مبيعات التذاكر في الملاعب الفعلية، وتابعت بعدها مسيرة النجاح وتحطيم الأرقام القياسية الجديدة باستمرار. وفي الآونة الأخيرة تعاونت شركة ” ساندبوكس في آر ” مع ” نتفليكس ” للإعلان عن استحواذها لفترة محدودة على موقعها في لندن للاحتفال بإصدار “Rebel Moon_ Part Two: The Scargiver” حيث قام الزوار بتجربة عالم “Rebel Moon” الافتراضي التفاعلي بكامل الجسم. ولمزيد من المعلومات والتفاصيل يرجى زيارة Sandboxvr.com أو إرسال الاستفسارات عبر حسابات التواصل الاجتماعي انستقرام وفيسبوك وتيك توك.

لمحة عن مجموعة أباريل

تقف مجموعة أباريل، أكبر مشغل في مجالات الأزياء وأسلوب الحياة، على مفترق طرق الاقتصاد الحديث في مدينة دبي، بدولة الإمارات العربية المتحدة. واليوم، أضحت المجموعة قادرة على تلبية احتياجات ملايين المتسوقين عبر أكثر من 2,200 متجراً وأكثر من 85 علامة تجارية وبفريق من 22,000 موظف من مختلف الثقافات.

حققت المجموعة حضوراً قوياً وراسخاً في دول مجلس التعاون الخليجي كما أنها نجحت في توسيع مجالات تسويقها في الهند وجنوب أفريقيا وسنغافورة واندونيسيا وتايلند وماليزيا ومصر. وإضافة إلى ذلك، وضعت المجموعة استراتيجيات واضحة للدخول إلى العديد من الأسواق الناشئة مثل هنغاريا والفليبين.

تدير مجموعة أباريل العديد من العلامات التجارية العالمية الشهيرة، التي انطلقت من الولايات المتحدة الأمريكية وكندا وأوروبا وأستراليا وآسيا، وتضم الكثير من الأسماء الرائدة في عالم الأزياء، الأحذية ونمط الحياة على غرار تومي هيلفيغر، تشارلز آند كيث، سكتشرز، ألدو، ناين وست، إروبوستال، وغيرها من الأسماء بالإضافة لعلامات تجارية رئيسية مثل تيم هورتنز، جيميز إتاليان، كولدستون كريمري، إنجلوت، ريتوالز وذلك على سبيل المثال لا الحصر.

يذكر بأن الفضل في نجاحات مجموعة أباريل ونموها المذهل يعود لرؤية وتوجيهات مؤسستها ورئيسة مجلس الإدارة سيما جنواني فيد، التي انطلقت بالشركة من القوة إلى الأقوى منذ نشأتها وعلى امتداد عقدين من الزمن.

https://apparelglobal.com/ar/

لمحة عن Sandbox VR “ساندبوكس في آر”

 “ساندبوكس في آر” هي الوجهة الرائدة الأولى من نوعها في العالم لألعاب الواقع الافتراضي المقدمة في الموقع. أنشأت الشركة منصة الواقع الافتراضي الغامرة التفاعلية بالكامل والأكثر تشويقاً على الإطلاق وتفتخر بالألعاب التي لا يمكن تجربتها في أي مكان آخر. “ساندبوكس في آر” تنشط حالياً في 46 موقعاً عبر سبع دول وتتوسع باستمرار وبوتيرة سريعة. ويقع المقر الرئيسي لشركة ” ساندبوكس في آر” في سان فرانسيسكو، كاليفورنيا ولها مكاتب في هونغ كونغ وفانكوفر. وجمعت الجولة الأخيرة من ” ساندبوكس في آر” 37 مليون دولار أمريكي من المستثمرين بما فيهم Andreessen Horowitz, Alibaba Entrepreneurs Fund, Gobi Partners, and Craft. ومن المستثمرين الأفراد جستن تيمبرلك وكاتي بيري وكيفن دورانت وويل سميث.

التواصل مع الإعلام

PR@apparelglobal.com

sandboxvr@inkhouse.com

 الصورة المصاحبة لهذا الإعلان متاحة على
https://www.globenewswire.com/NewsRoom/AttachmentNg/ec651223-8fa3-4aef-8518-a2993aeabeea/ar

GlobeNewswire Distribution ID 9113692